StockMacro
Company, fund or insider

Help

Menu

Acumen Pharmaceuticals

$0.19 -92% in 6 monthsMarket cap $13.5M

ABOS on XNAS, Health Care, Acumen Pharmaceuticals, Inc., job postings

Measures activity, not value. Not investment advice.

Shares down 91% in a month after restructuring filing, though cash $78.6M tops $14M market cap.

  • BadShort interest up 47% in two weeks to 6.3% of shares

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
61
Website
acumenpharm.com
Listed
Nasdaq, US
Last results
26 Oct 2026
Next results
expected around 25 Mar 2027 (an estimate: a year ago it reported on 26 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $25.4M.
Quarter to 31 Dec 2021: revenue –, net income -$8.3MQuarter to 31 Mar 2022: revenue –, net income -$9.1MQuarter to 30 Jun 2022: revenue –, net income -$10.2MQuarter to 30 Sep 2022: revenue –, net income -$10.7MQuarter to 31 Dec 2022: revenue –, net income -$12.9MQuarter to 31 Mar 2023: revenue –, net income -$11.3MQuarter to 30 Jun 2023: revenue –, net income -$11.6MQuarter to 30 Sep 2023: revenue –, net income -$13.0MQuarter to 31 Dec 2023: revenue –, net income -$16.5MQuarter to 31 Mar 2024: revenue –, net income -$14.9MQuarter to 30 Jun 2024: revenue –, net income -$20.5MQuarter to 30 Sep 2024: revenue –, net income -$29.8MQuarter to 31 Dec 2024: revenue –, net income -$37.2MQuarter to 31 Mar 2025: revenue –, net income -$28.8MQuarter to 30 Jun 2025: revenue –, net income -$41.0MQuarter to 30 Sep 2025: revenue –, net income -$26.5MQuarter to 31 Dec 2025: revenue –, net income -$25.1MQuarter to 31 Mar 2026: revenue –, net income -$20.7MQuarter to 30 Jun 2026: revenue –, net income -$32.7MQuarter to 30 Sep 2026: revenue –, net income -$25.4M
31 Dec 2021RevenueNet incomeNet losstallest bar $41.0M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$25.4M
30 Jun 2026–-$32.7M
31 Mar 2026–-$20.7M
31 Dec 2025–-$25.1M
30 Sep 2025–-$26.5M
30 Jun 2025–-$41.0M
31 Mar 2025–-$28.8M
31 Dec 2024–-$37.2M
30 Sep 2024–-$29.8M
30 Jun 2024–-$20.5M
31 Mar 2024–-$14.9M
31 Dec 2023–-$16.5M
30 Sep 2023–-$13.0M
30 Jun 2023–-$11.6M
31 Mar 2023–-$11.3M
31 Dec 2022–-$12.9M
30 Sep 2022–-$10.7M
30 Jun 2022–-$10.2M
31 Mar 2022–-$9.1M
31 Dec 2021–-$8.3M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$104.0M -$133.4M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$1.54 -$2.22
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -163% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $78.6M $126.6M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $26.3M $30.7M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$52.3M (net cash) -$96.0M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.76 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.48
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.39 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Acumen PharmaceuticalsABOS (this company) $13.5Mloss–––
PluriPLUR $13.5Mloss9.3+10%–
Estrella ImmunopharmaESLA $14.1Mloss–––
Passage BioPASG $12.6Mloss–––
BioStem TechnologiesBSEM $12.2M––––
BioCardiaBCDA $11.9Mloss–––

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-6.2%

91 13F filers vs 97

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

67%

48.5M shares held by 13F filers (30 Sep 2026) of 72.3M outstanding (21 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

6.3%

4.6M shares sold short (30 Oct 2026) of 72.3M outstanding (21 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.0

4.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+47%

3.1M shares sold short in the report before, 4.6M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

54%

54% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 47%

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

3

3 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

3 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $0.19 on 20 Nov 2026, -88% over 12 months (12-month range $0.19 to $3.37)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $626K in the last 12 months (the 12 months before: -$259K).
Capital spending per quarter. Capital spending $0 in the latest quarter.
Institutional holders (13F filers). 91 13F filers reported holding it in the latest 13F quarter, +42% on a year earlier.
Federal obligations. Federal obligations: $0 published in the last 12 months.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
5 Nov 20268-K and other filingsRestructuring costs announced
5 Nov 20268-K and other filingsA major agreement ended
18 Aug 2026Sharp changeShort interest spike: short interest spike, 3.4M vs usual 1.3M (2026-07-31); 2.4x the same period a year earlier
10 Nov 20258-K and other filingsDirector or officer change
10 Nov 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Jul 2025Sharp changeShort interest spike: short interest spike, 2.7M vs usual 1.7M (2025-06-13); 3.8x the same period a year earlier
17 Jun 2025Sharp changeShort interest spike: short interest spike, 2.5M vs usual 1.7M (2025-05-30); 3.6x the same period a year earlier
1 Feb 20248-K and other filingsDirector or officer change
1 Feb 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Oct 2023Sharp changeShort interest spike: short interest spike, 1.8M vs usual 614K (2023-09-15); 2.5x the same period a year earlier
19 Sep 2023Sharp changeShort interest spike: short interest spike, 1.8M vs usual 614K (2023-08-31); 2.5x the same period a year earlier
29 Aug 2023Sharp changeShort interest spike: short interest spike, 1.6M vs usual 614K (2023-08-15); 1.6x the same period a year earlier
15 Aug 2023Sharp changeShort interest spike: short interest spike, 1.5M vs usual 614K (2023-07-31); 1.9x the same period a year earlier
4 Jan 20238-K and other filingsDirector or officer change
4 Jan 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Oct 2022Sharp changeShort interest spike: short interest spike, 2.4M vs usual 963K (2022-09-30); 3.5x the same period a year earlier
15 Aug 20228-K and other filingsDirector or officer change
15 Aug 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Jan 20228-K and other filingsDirector or officer change
3 Jan 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Jul 2023: $40.0M published
Month from 1 Aug 2023: -$272K published
Month from 1 Jan 2024: -$122K published
Month from 1 Jan 2025: -$259K published
Month from 1 Jan 2026: -$501K published
Month from 1 Mar 2026: -$35K published
Month from 1 Jun 2026: -$90K published
Capital spending per quarter
Quarter ended 31 Dec 2021: $26K; public on 29 Mar 2022
Quarter ended 31 Mar 2022: $9K; public on 17 May 2022
Quarter ended 30 Jun 2022: $36K; public on 16 Aug 2022
Quarter ended 30 Sep 2022: $81K, +912% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $35K, +35% on a year earlier; public on 28 Mar 2023
Quarter ended 31 Mar 2023: $0, -100% on a year earlier; public on 10 May 2023
Quarter ended 30 Sep 2023: $7K, -91% on a year earlier; public on 14 Nov 2023
Quarter ended 31 Dec 2023: $14K, -60% on a year earlier; public on 27 Mar 2024
Quarter ended 31 Mar 2024: $11K; public on 15 May 2024
Quarter ended 30 Jun 2024: $5K; public on 14 Aug 2024
Quarter ended 31 Mar 2025: $79K, +618% on a year earlier; public on 14 May 2025
Quarter ended 30 Jun 2025: $9K, +80% on a year earlier; public on 13 Aug 2025
Quarter ended 31 Mar 2026: $0, -100% on a year earlier; public on 13 May 2026
Quarter ended 30 Jun 2026: $0, -100% on a year earlier; public on 13 Aug 2026
Quarter ended 30 Sep 2026: $0; public on 27 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 50; public on 14 Feb 2022
31 Mar 2022 report: 55; public on 16 May 2022
30 Jun 2022 report: 46; public on 15 Aug 2022
30 Sep 2022 report: 49; public on 14 Nov 2022
31 Dec 2022 report: 59; public on 14 Feb 2023
31 Mar 2023 report: 57; public on 15 May 2023
30 Jun 2023 report: 47; public on 14 Aug 2023
30 Sep 2023 report: 62; public on 14 Nov 2023
31 Dec 2023 report: 62; public on 14 Feb 2024
31 Mar 2024 report: 78; public on 15 May 2024
30 Jun 2024 report: 77; public on 14 Aug 2024
30 Sep 2024 report: 70; public on 14 Nov 2024
31 Dec 2024 report: 79; public on 14 Feb 2025
31 Mar 2025 report: 79; public on 15 May 2025
30 Jun 2025 report: 67; public on 14 Aug 2025
30 Sep 2025 report: 64; public on 14 Nov 2025
31 Dec 2025 report: 69; public on 17 Feb 2026
31 Mar 2026 report: 82; public on 15 May 2026
30 Jun 2026 report: 97; public on 14 Aug 2026
30 Sep 2026 report: 91; public on 16 Nov 2026
Federal obligations
Month from 1 Apr 2023: -$109K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is short interest change vs previous settlement, % (as published by FINRA) at 47.4 (30 Oct 2026), 18× its normal reading; higher than 90% of its own history.
  • Short interest spike: had 3.4M shares sold short in the 31 Jul 2026 report, 2.4× the same report last year Public on 12 Aug 2026.
  • Insider net buying (open market): Insiders sold a net $626K in the last 12 months (the 12 months before: -$259K).
  • Capital spending per quarter: Capital spending $0 in the latest quarter.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 45 insider trades

No trades in the last 90 days; the latest was filed 17 Jun 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
17 Jun 2026Derrell PorterDirectorSellafter exercising options32,300$2.33$75KForm 4
10 Jun 2026Nathan B FountainDirectorSell6,400$2.23$14KForm 4
10 Mar 2026Derek M MeisnerChief Legal Officer & Corp SecSellplanned in advance (10b5-1); after exercising options2,090$3.26$7KForm 4
3 Mar 2026Derek M MeisnerChief Legal Officer & Corp SecSellplanned in advance (10b5-1); after exercising options9,406$3.01$28KForm 4
28 Jan 2026Derek M MeisnerChief Legal Officer & Corp SecSellplanned in advance (10b5-1); after exercising options17,756$3.00$53KForm 4
23 Jan 2026Russell BartonChief Operating OfficerSell2,777$1.81$5KForm 4
23 Jan 2026Daniel Joseph OConnellChief Executive OfficerSell12,035$1.83$22KForm 4
23 Jan 2026Matt ZugaCFO & Chief Business OfficerSell4,160$1.83$8KForm 4

91 institutions reported shares at the end of Q3 2026, 67% of the shares outstanding; 6 opened a position, 11 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Ra Capital Management, L.P.21.0M29.0%$46.6MNo change
Sands Capital Alternatives, LLC3.7M5.14%$8.3MNo change
BlackRock, Inc.2.8M3.87%$6.2M+312K+13%
Franklin Templeton Inc2.3M3.19%$499KNo change
ADAR1 Capital Management, LLC2.1M2.92%$4.7M+3,000+0.1%
Vanguard Capital Management LLC1.8M2.51%$4.0M+144K+8.6%
Knollwood Investment Advisory, LLC1.6M2.25%$3.6MNo change
Alyeska Investment Group, L.P.1.6M2.20%$3.5M-862K-35%
Geode Capital Management, LLC1.2M1.60%$2.6M+13K+1.1%
Rosalind Advisors, Inc.1.1M1.52%$2.4MNew+1.1M

Company events

All 14 company events

In 12 months: 1 major agreement, 1 agreement ended, 1 restructuring. Results releases and routine reports are left out.

FiledWhat happenedSource
5 Nov 2026A major agreement ended; Restructuring costs announced8-K
16 Mar 2026Signed a major agreementSame filing: sold shares privately8-K
10 Nov 2025Director or officer change8-K
15 Jul 2025Signed a major agreement8-K
1 Feb 2024Director or officer change8-K
8 Nov 2023Signed a major agreement8-K
20 Jul 2023Signed a major agreement8-K
27 Apr 2023Signed a major agreement8-K

The 5 newest of 54 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 5 Nov 2026Filings record

    Restructuring costs announced

  2. 5 Nov 2026Filings record

    A major agreement ended

  3. 12 Aug 2026Short interest and volume change

    had 3.4M shares sold short in the 31 Jul 2026 report, 2.4× the same report last year.

    Same report last year: 1.4M; its normal report is 1.3M.

    See the evidence
    This period
    3.4M (the 31 Jul 2026 report)
    Normal report (median of 24 earlier)
    1.3M
    Typical spread (median absolute deviation)
    358K
    How far from its usual level
    +3.8
    Same report last year
    1.4M
    History used
    1,842 days
    2025-07-31: 1.4M2025-08-15: 1.4M2025-08-29: 1.4M2025-09-15: 1.4M2025-09-30: 1.3M2025-10-15: 1.3M2025-10-31: 1.4M2025-11-14: 1.3M2025-11-28: 575K2025-12-15: 568K2025-12-31: 554K2026-01-15: 600K2026-01-30: 900K2026-02-13: 947K2026-02-27: 961K2026-03-13: 1.0M2026-03-31: 1.1M2026-04-15: 1.5M2026-04-30: 1.7M2026-05-15: 1.7M2026-05-29: 1.9M2026-06-15: 1.9M2026-06-30: 2.8M2026-07-15: 2.8M2026-07-31: 3.4M
    the 31 Jul 2026 report24 earlier reportsnormal: 1.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  4. 10 Nov 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 10 Nov 2025Filings record

    Director or officer change

  6. 26 Jun 2025Short interest and volume change

    had 2.7M shares sold short in the 13 Jun 2025 report, 3.8× the same report last year.

    Same report last year: 711K; its normal report is 1.7M.

    See the evidence
    This period
    2.7M (the 13 Jun 2025 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    142K
    How far from its usual level
    +4.7
    Same report last year
    711K
    History used
    1,429 days
    2024-06-14: 711K2024-06-28: 990K2024-07-15: 1.7M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.7M2024-09-13: 1.7M2024-09-30: 1.6M2024-10-15: 1.3M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.4M2024-12-31: 1.6M2025-01-15: 1.8M2025-01-31: 1.8M2025-02-14: 1.7M2025-02-28: 1.8M2025-03-14: 1.8M2025-03-31: 1.7M2025-04-15: 1.8M2025-04-30: 1.7M2025-05-15: 1.9M2025-05-30: 2.5M2025-06-13: 2.7M
    the 13 Jun 2025 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 11 Jun 2025Short interest and volume change

    had 2.5M shares sold short in the 30 May 2025 report, 3.6× the same report last year.

    Same report last year: 708K; its normal report is 1.7M.

    See the evidence
    This period
    2.5M (the 30 May 2025 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    160K
    How far from its usual level
    +3.7
    Same report last year
    708K
    History used
    1,415 days
    2024-05-31: 708K2024-06-14: 711K2024-06-28: 990K2024-07-15: 1.7M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.7M2024-09-13: 1.7M2024-09-30: 1.6M2024-10-15: 1.3M2024-10-31: 1.4M2024-11-15: 1.5M2024-11-29: 1.4M2024-12-13: 1.4M2024-12-31: 1.6M2025-01-15: 1.8M2025-01-31: 1.8M2025-02-14: 1.7M2025-02-28: 1.8M2025-03-14: 1.8M2025-03-31: 1.7M2025-04-15: 1.8M2025-04-30: 1.7M2025-05-15: 1.9M2025-05-30: 2.5M
    the 30 May 2025 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 1 Feb 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  9. 1 Feb 2024Filings record

    Director or officer change

  10. 27 Sep 2023Short interest and volume change

    had 1.8M shares sold short in the 15 Sep 2023 report, 2.5× the same report last year.

    Same report last year: 698K; its normal report is 614K.

    See the evidence
    This period
    1.8M (the 15 Sep 2023 report)
    Normal report (median of 24 earlier)
    614K
    Typical spread (median absolute deviation)
    212K
    How far from its usual level
    +3.7
    Same report last year
    698K
    History used
    792 days
    2022-09-15: 698K2022-09-30: 2.4M2022-10-14: 1.3M2022-10-31: 1.0M2022-11-15: 776K2022-11-30: 705K2022-12-15: 876K2022-12-30: 572K2023-01-13: 604K2023-01-31: 610K2023-02-15: 597K2023-02-28: 634K2023-03-15: 618K2023-03-31: 598K2023-04-14: 590K2023-04-28: 217K2023-05-15: 160K2023-05-31: 240K2023-06-15: 151K2023-06-30: 191K2023-07-14: 610K2023-07-31: 1.5M2023-08-15: 1.6M2023-08-31: 1.8M2023-09-15: 1.8M
    the 15 Sep 2023 report24 earlier reportsnormal: 614K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 13 Sep 2023Short interest and volume change

    had 1.8M shares sold short in the 31 Aug 2023 report, 2.5× the same report last year.

    Same report last year: 700K; its normal report is 614K.

    See the evidence
    This period
    1.8M (the 31 Aug 2023 report)
    Normal report (median of 24 earlier)
    614K
    Typical spread (median absolute deviation)
    126K
    How far from its usual level
    +6.1
    Same report last year
    700K
    History used
    777 days
    2022-08-31: 700K2022-09-15: 698K2022-09-30: 2.4M2022-10-14: 1.3M2022-10-31: 1.0M2022-11-15: 776K2022-11-30: 705K2022-12-15: 876K2022-12-30: 572K2023-01-13: 604K2023-01-31: 610K2023-02-15: 597K2023-02-28: 634K2023-03-15: 618K2023-03-31: 598K2023-04-14: 590K2023-04-28: 217K2023-05-15: 160K2023-05-31: 240K2023-06-15: 151K2023-06-30: 191K2023-07-14: 610K2023-07-31: 1.5M2023-08-15: 1.6M2023-08-31: 1.8M
    the 31 Aug 2023 report24 earlier reportsnormal: 614K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 25 Aug 2023Short interest and volume change

    had 1.6M shares sold short in the 15 Aug 2023 report, 1.6× the same report last year.

    Same report last year: 1.0M; its normal report is 614K.

    See the evidence
    This period
    1.6M (the 15 Aug 2023 report)
    Normal report (median of 24 earlier)
    614K
    Typical spread (median absolute deviation)
    126K
    How far from its usual level
    +5.4
    Same report last year
    1.0M
    History used
    761 days
    2022-08-15: 1.0M2022-08-31: 700K2022-09-15: 698K2022-09-30: 2.4M2022-10-14: 1.3M2022-10-31: 1.0M2022-11-15: 776K2022-11-30: 705K2022-12-15: 876K2022-12-30: 572K2023-01-13: 604K2023-01-31: 610K2023-02-15: 597K2023-02-28: 634K2023-03-15: 618K2023-03-31: 598K2023-04-14: 590K2023-04-28: 217K2023-05-15: 160K2023-05-31: 240K2023-06-15: 151K2023-06-30: 191K2023-07-14: 610K2023-07-31: 1.5M2023-08-15: 1.6M
    the 15 Aug 2023 report24 earlier reportsnormal: 614K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 10 Aug 2023Short interest and volume change

    had 1.5M shares sold short in the 31 Jul 2023 report, 1.9× the same report last year.

    Same report last year: 810K; its normal report is 614K.

    See the evidence
    This period
    1.5M (the 31 Jul 2023 report)
    Normal report (median of 24 earlier)
    614K
    Typical spread (median absolute deviation)
    126K
    How far from its usual level
    +5.0
    Same report last year
    810K
    History used
    746 days
    2022-07-29: 810K2022-08-15: 1.0M2022-08-31: 700K2022-09-15: 698K2022-09-30: 2.4M2022-10-14: 1.3M2022-10-31: 1.0M2022-11-15: 776K2022-11-30: 705K2022-12-15: 876K2022-12-30: 572K2023-01-13: 604K2023-01-31: 610K2023-02-15: 597K2023-02-28: 634K2023-03-15: 618K2023-03-31: 598K2023-04-14: 590K2023-04-28: 217K2023-05-15: 160K2023-05-31: 240K2023-06-15: 151K2023-06-30: 191K2023-07-14: 610K2023-07-31: 1.5M
    the 31 Jul 2023 report24 earlier reportsnormal: 614K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 26 Jul 2023Insiders record

    RA CAPITAL MANAGEMENT, L.P. (director) and 4 other(s) bought 5,161,290 shares of ABOS ($40.0M) (dated 25 Jul 2023)

  15. 4 Jan 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  16. 4 Jan 2023Filings record

    Director or officer change

  17. 13 Oct 2022Short interest and volume change

    had 2.4M shares sold short in the 30 Sep 2022 report, 3.5× the same report last year.

    Same report last year: 678K; its normal report is 963K.

    See the evidence
    This period
    2.4M (the 30 Sep 2022 report)
    Normal report (median of 24 earlier)
    963K
    Typical spread (median absolute deviation)
    264K
    How far from its usual level
    +3.6
    Same report last year
    678K
    History used
    442 days
    2021-09-15: 139K2021-09-30: 678K2021-10-15: 958K2021-10-29: 668K2021-11-15: 650K2021-11-30: 594K2021-12-15: 973K2022-01-14: 968K2022-01-31: 1.0M2022-02-15: 916K2022-02-28: 952K2022-03-15: 1.2M2022-03-31: 1.7M2022-04-14: 1.8M2022-04-29: 1.9M2022-05-13: 2.0M2022-05-31: 2.2M2022-06-15: 2.0M2022-06-30: 1.1M2022-07-15: 949K2022-07-29: 810K2022-08-15: 1.0M2022-08-31: 700K2022-09-15: 698K2022-09-30: 2.4M
    the 30 Sep 2022 report24 earlier reportsnormal: 963K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 15 Aug 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  19. 15 Aug 2022Filings record

    Director or officer change

  20. 3 Jan 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  21. 3 Jan 2022Filings record

    Director or officer change

  22. 9 Jul 2021Insiders change

    had 5 insiders buy $54.4M of its shares on the open market within 30 days (6 filings).

    Who bought: Stalfort John A III, Hardie Robert D., Fountain Nathan B.

    See the evidence (6 source records)
    Independent buyers
    5
    Purchase filings (Form 4, code P)
    6
    Total bought
    $54.4M
    Window
    9 Jun 2021 to 9 Jul 2021

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  23. 9 Jul 2021Insiders record

    Fountain Nathan B (director) bought 6,250 shares of ABOS ($100,000) (dated 8 Jul 2021)

  24. 9 Jul 2021Insiders record

    Hardie Robert D. (ten percent owner) bought 750,000 shares of ABOS ($12.0M) (dated 8 Jul 2021)

  25. 9 Jul 2021Insiders record

    Shah Rajeev M. (director) and 4 other(s) bought 1,875,000 shares of ABOS ($30.0M) (dated 8 Jul 2021)

  26. 9 Jul 2021Insiders record

    SANDS FRANK M. (ten percent owner) and 3 other(s) bought 450,000 shares of ABOS ($6.7M) (dated 8 Jul 2021)

  27. 9 Jul 2021Insiders record

    Hardie Robert D. (ten percent owner) bought 312,500 shares of ABOS ($5.0M) (dated 8 Jul 2021)

  28. 9 Jul 2021Insiders record

    Stalfort John A III (director) bought 35,000 shares of ABOS ($560,000) (dated 8 Jul 2021)

  29. 9 Jul 2021Insiders record

    Manning Paul B (ten percent owner) bought 312,500 shares of ABOS [same transaction as an earlier filing] (dated 8 Jul 2021)

  30. 24 Jun 2021Filings record

    Registered new securities for sale (S-1)

  31. 9 Jun 2021Filings record

    Registered new securities for sale (S-1)

Not listed: 95 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001576885
Ticker
ABOS
Domain
acumenpharm.com
Hq location
MA|NEWTON|02465 (1 unverified)
Name
Acumen Pharmaceuticals, Inc.
Uei
YHM4FW9X3YC3
  • SEC Form 13F institutional holdings189 data points30 Sep 2021 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)67 records9 Jun 2021 to 5 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)349 data points31 Dec 2019 to 21 Oct 2026
  • SEC Form 4 insider transactions45 records, 60 data points8 Jul 2021 to 17 Jun 2026
  • FINRA short interest (twice monthly)380 data points15 Jul 2021 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2710 data points1 Jul 2021 to 20 Nov 2026
  • USASpending.gov federal awards33 data points16 Sep 2014 to 17 Mar 2023